Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 191

1.

Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.

Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, Colcher D, Shively J, Cristea M, Forman SJ, Priceman SJ.

Front Immunol. 2018 Nov 19;9:2268. doi: 10.3389/fimmu.2018.02268. eCollection 2018.

2.

Template-Catalyzed, Disulfide Conjugation of Monoclonal Antibodies Using a Natural Amino Acid Tag.

King JD, Ma Y, Kuo YC, Bzymek KP, Goodstein LH, Meyer K, Moore RE, Crow D, Colcher DM, Singh G, Horne DA, Williams JC.

Bioconjug Chem. 2018 Jun 20;29(6):2074-2081. doi: 10.1021/acs.bioconjchem.8b00284. Epub 2018 May 25.

PMID:
29763554
3.

PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine.

Weist MR, Starr R, Aguilar B, Chea J, Miles JK, Poku E, Gerdts E, Yang X, Priceman SJ, Forman SJ, Colcher D, Brown CE, Shively JE.

J Nucl Med. 2018 Oct;59(10):1531-1537. doi: 10.2967/jnumed.117.206714. Epub 2018 May 4.

4.

Mechanically interlocked functionalization of monoclonal antibodies.

Bzymek KP, Puckett JW, Zer C, Xie J, Ma Y, King JD, Goodstein LH, Avery KN, Colcher D, Singh G, Horne DA, Williams JC.

Nat Commun. 2018 Apr 20;9(1):1580. doi: 10.1038/s41467-018-03976-5.

5.

Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.

Caserta E, Chea J, Minnix M, Poku EK, Viola D, Vonderfecht S, Yazaki P, Crow D, Khalife J, Sanchez JF, Palmer JM, Hui S, Carlesso N, Keats J, Kim Y, Buettner R, Marcucci G, Rosen S, Shively J, Colcher D, Krishnan A, Pichiorri F.

Blood. 2018 Feb 15;131(7):741-745. doi: 10.1182/blood-2017-09-807263. Epub 2018 Jan 4. Erratum in: Blood. 2018 Jun 21;131(25):2869.

6.

Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model.

Wong P, Li L, Chea J, Delgado MK, Poku E, Szpikowska B, Bowles N, Minnix M, Colcher D, Wong JYC, Shively JE, Yazaki PJ.

Cancer Biother Radiopharm. 2017 Sep;32(7):247-257.

7.

Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma.

Cahan B, Leong L, Wagman L, Yamauchi D, Shibata S, Wilzcynski S, Williams LE, Yazaki P, Colcher D, Frankel P, Wu A, Raubitschek A, Shively J, Wong JYC.

Cancer Biother Radiopharm. 2017 Sep;32(7):258-265.

8.

Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.

Mortimer JE, Bading JR, Park JM, Frankel PH, Carroll MI, Tran TT, Poku EK, Rockne RC, Raubitschek AA, Shively JE, Colcher DM.

J Nucl Med. 2018 Jan;59(1):38-43. doi: 10.2967/jnumed.117.193888. Epub 2017 Jun 21. Erratum in: J Nucl Med. 2018 Feb;59(2):346.

9.

Diagnostic PET Imaging of Mammary Microcalcifications Using 64Cu-DOTA-Alendronate in a Rat Model of Breast Cancer.

Ahrens BJ, Li L, Ciminera AK, Chea J, Poku E, Bading JR, Weist MR, Miller MM, Colcher DM, Shively JE.

J Nucl Med. 2017 Sep;58(9):1373-1379. doi: 10.2967/jnumed.117.190850. Epub 2017 Apr 27.

10.

PET imaging of 64Cu-DOTA-scFv-anti-PSMA lipid nanoparticles (LNPs): Enhanced tumor targeting over anti-PSMA scFv or untargeted LNPs.

Wong P, Li L, Chea J, Delgado MK, Crow D, Poku E, Szpikowska B, Bowles N, Channappa D, Colcher D, Wong JYC, Shively JE, Yazaki PJ.

Nucl Med Biol. 2017 Apr;47:62-68. doi: 10.1016/j.nucmedbio.2017.01.004. Epub 2017 Jan 17.

11.

Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells.

Sta Maria NS, Barnes SR, Weist MR, Colcher D, Raubitschek AA, Jacobs RE.

PLoS One. 2015 Nov 10;10(11):e0142767. doi: 10.1371/journal.pone.0142767. eCollection 2015.

12.

Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.

Mortimer JE, Bading JR, Colcher DM, Conti PS, Frankel PH, Carroll MI, Tong S, Poku E, Miles JK, Shively JE, Raubitschek AA.

J Nucl Med. 2014 Jan;55(1):23-9. doi: 10.2967/jnumed.113.122630. Epub 2013 Dec 12.

13.

Site specific discrete PEGylation of (124)I-labeled mCC49 Fab' fragments improves tumor MicroPET/CT imaging in mice.

Ding H, Carlton MM, Povoski SP, Milum K, Kumar K, Kothandaraman S, Hinkle GH, Colcher D, Brody R, Davis PD, Pokora A, Phelps M, Martin EW Jr, Tweedle MF.

Bioconjug Chem. 2013 Nov 20;24(11):1945-54. doi: 10.1021/bc400375f. Epub 2013 Oct 31.

14.

Single molecular weight discrete PEG compounds: emerging roles in molecular diagnostics, imaging and therapeutics.

Povoski SP, Davis PD, Colcher D, Martin EW Jr.

Expert Rev Mol Diagn. 2013 May;13(4):315-9. doi: 10.1586/erm.13.19. No abstract available.

15.

Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101.

Ng TS, Wert D, Sohi H, Procissi D, Colcher D, Raubitschek AA, Jacobs RE.

Clin Cancer Res. 2013 May 1;19(9):2518-27. doi: 10.1158/1078-0432.CCR-12-2738. Epub 2013 Mar 26.

16.

A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.

Yazaki PJ, Lee B, Channappa D, Cheung CW, Crow D, Chea J, Poku E, Li L, Andersen JT, Sandlie I, Orcutt KD, Wittrup KD, Shively JE, Raubitschek A, Colcher D.

Protein Eng Des Sel. 2013 Mar;26(3):187-93. doi: 10.1093/protein/gzs096. Epub 2012 Nov 21.

17.

Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner.

Ng TS, Bading JR, Park R, Sohi H, Procissi D, Colcher D, Conti PS, Cherry SR, Raubitschek AA, Jacobs RE.

J Nucl Med. 2012 Jul;53(7):1102-9. doi: 10.2967/jnumed.111.099861. Epub 2012 Jun 1.

18.

In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor.

Wu Z, Todorov I, Li L, Bading JR, Li Z, Nair I, Ishiyama K, Colcher D, Conti PE, Fraser SE, Shively JE, Kandeel F.

Bioconjug Chem. 2011 Aug 17;22(8):1587-94. doi: 10.1021/bc200132t. Epub 2011 Jul 14.

PMID:
21692471
19.

A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells.

Wang X, Chang WC, Wong CW, Colcher D, Sherman M, Ostberg JR, Forman SJ, Riddell SR, Jensen MC.

Blood. 2011 Aug 4;118(5):1255-63. doi: 10.1182/blood-2011-02-337360. Epub 2011 Jun 7.

20.

Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging.

Li L, Crow D, Turatti F, Bading JR, Anderson AL, Poku E, Yazaki PJ, Carmichael J, Leong D, Wheatcroft D, Raubitschek AA, Hudson PJ, Colcher D, Shively JE.

Bioconjug Chem. 2011 Apr 20;22(4):709-16. doi: 10.1021/bc100464e. Epub 2011 Mar 24. Erratum in: Bioconjug Chem. 2011 Jun 15;22(6):1256. Wheatcroft, Michael P [corrected to Wheatcroft, David].

21.

A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.

Wong JY, Raubitschek A, Yamauchi D, Williams LE, Wu AM, Yazaki P, Shively JE, Colcher D, Somlo G.

Cancer Biother Radiopharm. 2010 Aug;25(4):387-94. doi: 10.1089/cbr.2010.0783.

22.

Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.

Li L, Turatti F, Crow D, Bading JR, Anderson AL, Poku E, Yazaki PJ, Williams LE, Tamvakis D, Sanders P, Leong D, Raubitschek A, Hudson PJ, Colcher D, Shively JE.

J Nucl Med. 2010 Jul;51(7):1139-46. doi: 10.2967/jnumed.109.074153. Epub 2010 Jun 16.

23.

Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.

Numbenjapon T, Wang J, Colcher D, Schluep T, Davis ME, Duringer J, Kretzner L, Yen Y, Forman SJ, Raubitschek A.

Clin Cancer Res. 2009 Jul 1;15(13):4365-73. doi: 10.1158/1078-0432.CCR-08-2619. Epub 2009 Jun 23.

24.

Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice.

Bading JR, Hörling M, Williams LE, Colcher D, Raubitschek A, Strand SE.

Cancer Biother Radiopharm. 2008 Aug;23(4):399-409. doi: 10.1089/cbr.2007.0457.

25.

Rapid and efficient production of radiolabeled antibody conjugates using vacuum diafiltration guided by mathematical modeling.

Bartlett DW, Colcher D, Raubitschek AA.

Bioconjug Chem. 2008 Sep;19(9):1927-37. doi: 10.1021/bc800223x. Epub 2008 Aug 23.

26.

Intratumoral immunocytokine treatment results in enhanced antitumor effects.

Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, Hank JA, Raubitschek A, Colcher D, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2008 Dec;57(12):1891-902. doi: 10.1007/s00262-008-0519-0. Epub 2008 Apr 26.

27.

Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein.

Yazaki PJ, Kassa T, Cheung CW, Crow DM, Sherman MA, Bading JR, Anderson AL, Colcher D, Raubitschek A.

Nucl Med Biol. 2008 Feb;35(2):151-8. doi: 10.1016/j.nucmedbio.2007.10.010.

28.

A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies.

Li L, Bading J, Yazaki PJ, Ahuja AH, Crow D, Colcher D, Williams LE, Wong JY, Raubitschek A, Shively JE.

Bioconjug Chem. 2008 Jan;19(1):89-96. Epub 2007 Nov 8.

29.

Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.

Singh H, Serrano LM, Pfeiffer T, Olivares S, McNamara G, Smith DD, Al-Kadhimi Z, Forman SJ, Gillies SD, Jensen MC, Colcher D, Raubitschek A, Cooper LJ.

Cancer Res. 2007 Mar 15;67(6):2872-80.

30.

Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.

Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, Shively JE, Colcher D, Raubitschek AA, Wu AM.

Cancer Res. 2007 Jan 15;67(2):718-26.

31.

Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.

Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, Osman M, Guthrie B, Schade-Bijur S, Hablitz DM, Alvarez VL, Gonda MA.

J Clin Oncol. 2006 Aug 1;24(22):3644-50.

PMID:
16877732
32.

Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody.

Li L, Yazaki PJ, Anderson AL, Crow D, Colcher D, Wu AM, Williams LE, Wong JY, Raubitschek A, Shively JE.

Bioconjug Chem. 2006 Jan-Feb;17(1):68-76.

PMID:
16417253
33.

Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.

Crow DM, Williams L, Colcher D, Wong JY, Raubitschek A, Shively JE.

Bioconjug Chem. 2005 Sep-Oct;16(5):1117-25.

PMID:
16173788
34.

Penetratin improves tumor retention of single-chain antibodies: a novel step toward optimization of radioimmunotherapy of solid tumors.

Jain M, Chauhan SC, Singh AP, Venkatraman G, Colcher D, Batra SK.

Cancer Res. 2005 Sep 1;65(17):7840-6.

35.

Imaging glioma extent with 131I-TM-601.

Hockaday DC, Shen S, Fiveash J, Raubitschek A, Colcher D, Liu A, Alvarez V, Mamelak AN.

J Nucl Med. 2005 Apr;46(4):580-6.

36.

Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.

Chauhan SC, Jain M, Moore ED, Wittel UA, Li J, Gwilt PR, Colcher D, Batra SK.

Eur J Nucl Med Mol Imaging. 2005 Mar;32(3):264-73. Epub 2004 Oct 2.

PMID:
15791435
37.

The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs.

Wittel UA, Jain M, Goel A, Chauhan SC, Colcher D, Batra SK.

Nucl Med Biol. 2005 Feb;32(2):157-64.

PMID:
15721761
38.

Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49.

Wittel UA, Jain M, Goel A, Baranowska-Kortylewicz J, Kurizaki T, Chauhan SC, Agrawal DK, Colcher D, Batra SK.

Biochem Biophys Res Commun. 2005 Apr 1;329(1):168-76.

PMID:
15721289
39.

Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.

Kenanova V, Olafsen T, Crow DM, Sundaresan G, Subbarayan M, Carter NH, Ikle DN, Yazaki PJ, Chatziioannou AF, Gambhir SS, Williams LE, Shively JE, Colcher D, Raubitschek AA, Wu AM.

Cancer Res. 2005 Jan 15;65(2):622-31.

40.

Humanization of the anti-CEA T84.66 antibody based on crystal structure data.

Yazaki PJ, Sherman MA, Shively JE, Ikle D, Williams LE, Wong JY, Colcher D, Wu AM, Raubitschek AA.

Protein Eng Des Sel. 2004 May;17(5):481-9. Epub 2004 Aug 17.

PMID:
15316127
41.

Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.

Wong JY, Chu DZ, Williams LE, Yamauchi DM, Ikle DN, Kwok CS, Liu A, Wilczynski S, Colcher D, Yazaki PJ, Shively JE, Wu AM, Raubitschek AA.

Clin Cancer Res. 2004 Aug 1;10(15):5014-21.

42.

Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies.

Cooper LJ, Al-Kadhimi Z, DiGiusto D, Kalos M, Colcher D, Raubitschek A, Forman SJ, Jensen MC.

Blood Cells Mol Dis. 2004 Jul-Aug;33(1):83-9. Review.

PMID:
15223016
43.

Determination and control of volatilized 131I released in the preparation of 131I tositumomab dosages for radioimmunotherapy.

Augustine SC, Colcher DM, Rutar FJ, Norenberg JP, Vang K.

J Am Pharm Assoc (2003). 2003 Sep-Oct;43(5):646-8. No abstract available.

PMID:
14626760
44.

Constructs of biotin mimetic peptide with CC49 single-chain Fv designed for tumor pretargeting.

Pavlinkova G, Batra SK, Colcher D, Booth BJ, Baranowska-Kortylewicz J.

Peptides. 2003 Mar;24(3):353-62.

PMID:
12732332
45.

Pharmacokinetics and biodistribution of genetically engineered antibodies.

Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D.

Curr Opin Biotechnol. 2002 Dec;13(6):603-8. Review.

PMID:
12482521
46.

Potentiation of radioimmunotherapy with response-selective peptide agonist of human C5a.

Kurizaki T, Okazaki S, Sanderson SD, Colcher D, Enke CA, Tempero MA, Baranowska-Kortylewicz J.

J Nucl Med. 2002 Jul;43(7):957-67.

47.

Binding to CD20 by anti-B1 antibody or F(ab')(2) is sufficient for induction of apoptosis in B-cell lines.

Cardarelli PM, Quinn M, Buckman D, Fang Y, Colcher D, King DJ, Bebbington C, Yarranton G.

Cancer Immunol Immunother. 2002 Mar;51(1):15-24. Epub 2001 Dec 18.

PMID:
11845256
48.

Combination therapy for non-Hodgkin's lymphoma: an opportunity for pharmaceutical care in a specialty practice.

Augustine SC, Norenberg JP, Colcher DM, Vose JM, Gobar LS, Dukat VJ, Hohenstein MA, Rutar FJ, Jacobson DA, Tempero MA.

J Am Pharm Assoc (Wash). 2002 Jan-Feb;42(1):93-100.

PMID:
11833524
49.

Feasibility and safety of outpatient Bexxar therapy (tositumomab and iodine I 131 tositumomab) for non-Hodgkin's lymphoma based on radiation doses to family members.

Rutar FJ, Augustine SC, Kaminski MS, Wahl RL, Siegel JA, Colcher D.

Clin Lymphoma. 2001 Dec;2(3):164-72. Review.

PMID:
11779293
50.

Effects of humanization and gene shuffling on immunogenicity and antigen binding of anti-TAG-72 single-chain Fvs.

Pavlinkova G, Colcher D, Booth BJ, Goel A, Wittel UA, Batra SK.

Int J Cancer. 2001 Dec 1;94(5):717-26.

Supplemental Content

Loading ...
Support Center